Russell Abberley, Amgen UK & Ireland, named as new ABPI Vice President

Russell Abberley, Amgen UK & Ireland, named as new ABPI Vice President

The Association of the British Pharmaceutical Industry (ABPI) has appointed Russell Abberley as Vice-President of the ABPI.

Russell will join and support ABPI President Susan Rienow, UK Managing Director and Country President of Pfizer, in delivering her presidential priorities and supporting the ABPI in its mission to make the UK the best place in the world to research, develop and use the medicines and vaccines of the future. Russell will take up his new role with immediate effect.

Russell is the General Manager of Amgen UK & Ireland and has over 25 years of life science industry experience across a range of geographies. He has served on the ABPI Board since July 2020, and was part of the industry Negotiating Team for the recently signed 2024 VPAG scheme.

Russell Abberley, ABPI Vice-President and VP and General Manager Amgen UK & Ireland, said: “I am honoured and delighted to join Susan in leading the ABPI, which plays a critical role in enabling the UK to remain a global leader in life science innovation. I’m looking forward to working closely with our members to deliver and improve access to innovative medicines, so that we can empower patients and improve health outcomes across the UK."

Susan Rienow, ABPI President and Country President, Pfizer UK, said: “I look forward to working alongside Russell at such a pivotal time for the life sciences industry and society more broadly. I know that his wealth of experience and patient-centred approach, will be a great asset to the ABPI as we work towards making the UK the best place in the world to develop and use medicines.”

Richard Torbett, ABPI Chief Executive, said: “We warmly welcome Russell into his new role of ABPI Vice-President. Russell brings in a wealth of experience and dedication which embody the values and vision we have to make the UK the best place in the world to research, develop and use the medicines and vaccines of the future.”

Russell’s expertise spans all stages of the product life cycle and he has worked across multiple therapy areas on originator medicines and biosimilars in commercial and operational roles at companies including Astra Zeneca, MSD and Schering Plough.

In addition to serving on the ABPI Board, he has chaired both the Clinical Trials Board Sponsored Group (BSG) along with the Commercial and VPAG BSG and was a member of the Governance Committee. Russell is a member of the American Pharmaceutical Group and served as Chair from August 2021 to October 2023.